PHIO - long - run up into preclinical data release

2024年2月29日

Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.

This is not a financial advice!

1 upcoming catalyst on 21st of March 2024

We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.

Shs. Float of 2.4

Keep an eye on 1.35 level, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.

SL under 0.85

TP approx. 2.10 maybe even 3.0

Most info on the chart.

Trade carefully!

2024年3月4日

交易結束：達到停損點